Fredrik Strand, a researcher at the Department of Oncology-Pathology at Karolinska Institutet and a radiologist at Karolinska University Hospital explained, “The studies show the potential of commercial AI algorithms as independent readers in screening mammography assessment on a clinically relevant level. The next step for us is to explore how well the Lunit AI algorithm works as an independent reader in a prospective clinical setting. In the future, I am convinced that AI image analysis will contribute to further improvements in overall survival for breast cancer patients.”
“As breast cancer is the second leading cause of death in women, early detection is the best defense in treating the disease,” says Brandon Suh, CEO of Lunit. “It is very meaningful for our algorithm’s high-performance level to be recognized in these well-designed studies based on a significant actual screening cohort data, and we hope to continuously provide the best solution for the right diagnosis of patients.”
ABOUT LUNIT
Perfecting Intelligence, Transforming Medicine.
With AI, we aim to make data-driven medicine the new standard of care. We are especially focused on conquering cancer, one of the leading causes of death worldwide. We develop AI solutions for precision diagnostics and therapeutics, to find the right diagnosis at the right cost, and the right treatment for the right patients.
Back to HCB News
